Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes

Miyoung Kim, Hoon Kook, Hyeon Jin Park, Hyo Seop Ahn, Kwang Chul Lee, Kun Soo Lee, Sang Kyu Park, Jae Young Lim, Hyun Kyung Kim, Dong Kyun Han, Dong Soon Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aims: Transcriptional repression of tumor suppressor genes is determined by the quantity of promoter hypermethylation. We analyzed the methylation quantity of CDKN2B in pediatric myelodysplastic syndromes (MDS). Methods: Quantitative measurement of CDKN2B methylation was performed in 25 pediatric MDS patients and 12 controls using pyrosequencing, and the result was compared with those from 74 adult MDS cases and 31 adult controls. The association between CDKN2B methylation quantity and factors related to prognosis including bone marrow blast percentage and karyotype was analyzed. Results: Pediatric MDS patients showed a higher methylation level (MtL) of CDKN2B than pediatric controls (2.94 vs. 1.62; p = 0.031) but a lower level than adult MDS patients (8.76; p < 0.001). MtL was higher in pediatric MDS cases with >5% blasts than in pediatric controls (3.78 vs. 1.62; p = 0.052). Pediatric MDS cases with abnormal karyotype showed a higher MtL than pediatric controls (5.95 vs. 1.62; p = 0.045). Conclusions: We confirmed that methylation of CDKN2B is associated with the pathogenesis and prognosis in pediatric MDS. The difference in MtLs between pediatric and adult MDS might be related to the physiological hypermethylation of tumor suppressor genes in aging.

Original languageEnglish
Pages (from-to)115-121
Number of pages7
JournalActa Haematologica
Volume130
Issue number2
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Myelodysplastic Syndromes
Methylation
Pediatrics
Tumor Suppressor Genes
Abnormal Karyotype
Karyotype
Bone Marrow

Keywords

  • CDKN2B
  • Methylation
  • Myelodysplasia
  • Pyrosequencing

ASJC Scopus subject areas

  • Hematology

Cite this

Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes. / Kim, Miyoung; Kook, Hoon; Park, Hyeon Jin; Ahn, Hyo Seop; Lee, Kwang Chul; Lee, Kun Soo; Park, Sang Kyu; Lim, Jae Young; Kim, Hyun Kyung; Han, Dong Kyun; Lee, Dong Soon.

In: Acta Haematologica, Vol. 130, No. 2, 01.08.2013, p. 115-121.

Research output: Contribution to journalArticle

Kim, M, Kook, H, Park, HJ, Ahn, HS, Lee, KC, Lee, KS, Park, SK, Lim, JY, Kim, HK, Han, DK & Lee, DS 2013, 'Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes', Acta Haematologica, vol. 130, no. 2, pp. 115-121. https://doi.org/10.1159/000347038
Kim, Miyoung ; Kook, Hoon ; Park, Hyeon Jin ; Ahn, Hyo Seop ; Lee, Kwang Chul ; Lee, Kun Soo ; Park, Sang Kyu ; Lim, Jae Young ; Kim, Hyun Kyung ; Han, Dong Kyun ; Lee, Dong Soon. / Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes. In: Acta Haematologica. 2013 ; Vol. 130, No. 2. pp. 115-121.
@article{d4f9836fdd314c30929eb71b48c2d3d6,
title = "Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes",
abstract = "Background/Aims: Transcriptional repression of tumor suppressor genes is determined by the quantity of promoter hypermethylation. We analyzed the methylation quantity of CDKN2B in pediatric myelodysplastic syndromes (MDS). Methods: Quantitative measurement of CDKN2B methylation was performed in 25 pediatric MDS patients and 12 controls using pyrosequencing, and the result was compared with those from 74 adult MDS cases and 31 adult controls. The association between CDKN2B methylation quantity and factors related to prognosis including bone marrow blast percentage and karyotype was analyzed. Results: Pediatric MDS patients showed a higher methylation level (MtL) of CDKN2B than pediatric controls (2.94 vs. 1.62; p = 0.031) but a lower level than adult MDS patients (8.76; p < 0.001). MtL was higher in pediatric MDS cases with >5{\%} blasts than in pediatric controls (3.78 vs. 1.62; p = 0.052). Pediatric MDS cases with abnormal karyotype showed a higher MtL than pediatric controls (5.95 vs. 1.62; p = 0.045). Conclusions: We confirmed that methylation of CDKN2B is associated with the pathogenesis and prognosis in pediatric MDS. The difference in MtLs between pediatric and adult MDS might be related to the physiological hypermethylation of tumor suppressor genes in aging.",
keywords = "CDKN2B, Methylation, Myelodysplasia, Pyrosequencing",
author = "Miyoung Kim and Hoon Kook and Park, {Hyeon Jin} and Ahn, {Hyo Seop} and Lee, {Kwang Chul} and Lee, {Kun Soo} and Park, {Sang Kyu} and Lim, {Jae Young} and Kim, {Hyun Kyung} and Han, {Dong Kyun} and Lee, {Dong Soon}",
year = "2013",
month = "8",
day = "1",
doi = "10.1159/000347038",
language = "English",
volume = "130",
pages = "115--121",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes

AU - Kim, Miyoung

AU - Kook, Hoon

AU - Park, Hyeon Jin

AU - Ahn, Hyo Seop

AU - Lee, Kwang Chul

AU - Lee, Kun Soo

AU - Park, Sang Kyu

AU - Lim, Jae Young

AU - Kim, Hyun Kyung

AU - Han, Dong Kyun

AU - Lee, Dong Soon

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background/Aims: Transcriptional repression of tumor suppressor genes is determined by the quantity of promoter hypermethylation. We analyzed the methylation quantity of CDKN2B in pediatric myelodysplastic syndromes (MDS). Methods: Quantitative measurement of CDKN2B methylation was performed in 25 pediatric MDS patients and 12 controls using pyrosequencing, and the result was compared with those from 74 adult MDS cases and 31 adult controls. The association between CDKN2B methylation quantity and factors related to prognosis including bone marrow blast percentage and karyotype was analyzed. Results: Pediatric MDS patients showed a higher methylation level (MtL) of CDKN2B than pediatric controls (2.94 vs. 1.62; p = 0.031) but a lower level than adult MDS patients (8.76; p < 0.001). MtL was higher in pediatric MDS cases with >5% blasts than in pediatric controls (3.78 vs. 1.62; p = 0.052). Pediatric MDS cases with abnormal karyotype showed a higher MtL than pediatric controls (5.95 vs. 1.62; p = 0.045). Conclusions: We confirmed that methylation of CDKN2B is associated with the pathogenesis and prognosis in pediatric MDS. The difference in MtLs between pediatric and adult MDS might be related to the physiological hypermethylation of tumor suppressor genes in aging.

AB - Background/Aims: Transcriptional repression of tumor suppressor genes is determined by the quantity of promoter hypermethylation. We analyzed the methylation quantity of CDKN2B in pediatric myelodysplastic syndromes (MDS). Methods: Quantitative measurement of CDKN2B methylation was performed in 25 pediatric MDS patients and 12 controls using pyrosequencing, and the result was compared with those from 74 adult MDS cases and 31 adult controls. The association between CDKN2B methylation quantity and factors related to prognosis including bone marrow blast percentage and karyotype was analyzed. Results: Pediatric MDS patients showed a higher methylation level (MtL) of CDKN2B than pediatric controls (2.94 vs. 1.62; p = 0.031) but a lower level than adult MDS patients (8.76; p < 0.001). MtL was higher in pediatric MDS cases with >5% blasts than in pediatric controls (3.78 vs. 1.62; p = 0.052). Pediatric MDS cases with abnormal karyotype showed a higher MtL than pediatric controls (5.95 vs. 1.62; p = 0.045). Conclusions: We confirmed that methylation of CDKN2B is associated with the pathogenesis and prognosis in pediatric MDS. The difference in MtLs between pediatric and adult MDS might be related to the physiological hypermethylation of tumor suppressor genes in aging.

KW - CDKN2B

KW - Methylation

KW - Myelodysplasia

KW - Pyrosequencing

UR - http://www.scopus.com/inward/record.url?scp=84875825778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875825778&partnerID=8YFLogxK

U2 - 10.1159/000347038

DO - 10.1159/000347038

M3 - Article

VL - 130

SP - 115

EP - 121

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2

ER -